Clinical trial
Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib…
NCT00440167 · PD Dr. med. Volker Heinemann, Other · Unknown status
Key facts
| NCT number | NCT00440167 |
|---|---|
| Title | Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine |
| Official title | Randomized Phase III Trial With Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine in Patients With Advanced Pancreatic Cancer |
| Lead sponsor | PD Dr. med. Volker Heinemann, Other |
| Collaborators | Roche Pharma AG Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Capecitabine, Erlotinib |
| Enrollment | 280 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2011 |
| Completion | Dec 1, 2012 |
| First posted | Feb 26, 2007 |
| Last update posted | Jul 9, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: